Drugs / bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03614702 | Sep 2015 → Aug 2016 | poliomyelitis | Institute of Medical Biology, Chinese Academy of Medical Sciences | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 | “bOPV (Candy): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Institute of Medical Biology,...” NCT03614702 ↗ |
| Known as | bOPV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03614702 ↗ |
| Modality | Vaccine | “bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3” NCT03614702 ↗ |
| Route | Oral | “followed by 2-doses bOPV(Candy) through mouth” NCT03614702 ↗ |